Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

• Sponsor: National Cancer Institute (NCI) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT00084682
• Collaborator: (none)
• Enrollment: 14
• Locations: 2
• Arm: 1
• Duration (Months): 81
• Patients Per Site: 7
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

This phase II trial is studying how well FR901228 works in treating patients with unresectable recurrent or metastatic squamous cell carcinoma (cancer) of the head and neck. Drugs used in chemotherapy such as FR901228 work in different ways to stop tumor cells from dividing so they stop growing or die.

Condition or Disease	Intervention/Treatment	Phase
Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Oropharynx	Drug: romidepsin	Phase 2

Detailed Description

PRIMARY OBJECTIVES:

1. To evaluate the rate of disease control (i.e., achievement of complete response, partial response, or stable disease) of the single agent depsipeptide in patients with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck.

SECONDARY OBJECTIVES:

1. To evaluate the duration of response, time to progression, and overall survival for patients with incurable head and neck cancer treated with depsipeptide.

TERTIARY OBJECTIVES:

1. To determine the extent of histone hyperacetylation in peripheral blood mononuclear cells (PBMCs) as a readout of depsipeptide activity before and after depsipeptide administration, to correlate this activity with observed histone hyperacetylation in tumor and mucosal cells, and to correlate extent of depsipeptide activity with tumor response.

2. To determine depsipeptide-induced changes in the gene expression profile of tumor cells from biopsies of accessible tumor tissue and of mucosal cells from transepithelial oral brush biopsies using cDNA microarrays containing 28,000 clones, and to correlate these changes with extent of histone hyperacetylation observed in PBMCs and tumor tissues.

3. To determine depsipeptide-induced changes in methylation of candidate genes in tumor cells and oral mucosa epithelia.

4. To demonstrate altered expression of signaling and cell cycle-related proteins in tumor tissue in response to depsipeptide.

OUTLINE: This is a multicenter study.

Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years.

Study Design

• Study Type: Interventional
• Actual Enrollment: 14 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of Single Agent Depsipeptide (FK228; NSC 630176; IND 51,810) in Patients With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
• Study Start Date: Jun 1, 2005
• Actual Primary Completion Date: Nov 1, 2008
• Actual Study Completion Date: Mar 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment (romidepsin) Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Drug: romidepsin; Given IV; Other Names: FK228 FR901228 Istodax

Outcome Measures

Primary Outcome Measures

1. Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease) [Up to 2 years]

   Tumor response was assessed every eight weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions as assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable disease (SD) was defined as having no evidence of response (CR or PR) as best response to therapy, and no evidence of disease progression (appearance of new lesions or >/= 30% increase in target lesions) at 8 weeks.

Secondary Outcome Measures

1. Duration of Response [Up to 2 years]

2. Time to Progression [Up to 2 years]

   All time to event endpoints will be evaluated using Kaplan Meier estimates and survival curves will be generated based on these estimates.

3. Overall Survival [Up to 2 years]

   All time to event endpoints will be evaluated using Kaplan Meier estimates and survival curves will be generated based on these estimates. One and two-year survival and median survival time (if attained) will be estimated and reported with 95% confidence limits. If the sample sizes are sufficient, subgroup analysis based on baseline factors will be performed using the log rank test to compare survival curves.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• histologically or cytologically confirmed squamous cell cancer of the head and neck (MedDRA code 90002024), excluding nasopharyngeal primaries, which is unresectable or metastatic; the disease must be incurable with surgery or radiation therapy; the tumor should preferably be present at the primary site, and it must be accessible to planned biopsy methods

• Measurable disease by RECIST,

• May have received any number of prior systemic chemotherapy regimen for unresectable, recurrent or metastatic disease; if the only site of measurable disease is a previously irradiated area, the patient must have documented progressive disease or biopsy-proven residual carcinoma; persistent disease after radiotherapy must be biopsy-proven at least 8 weeks after the completion of radiotherapy

• Life expectancy of greater than 3 months

• Normal organ and marrow function as defined by the following labs performed =< 2 weeks of study entry:

• Leukocytes ≥ 3,000/uL

• Absolute Neutrophil Count ≥ 1,500/uL

• Hemoglobin ≥ 10 gm%

• Platelets ≥ 100,000/uL

• Total Bilirubin =< 1.5 X upper normal institutional limit

• AST(SGOT)/ALT(SGPT) =< 2.5 X upper normal institutional limits

• Creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

• PT/PTT =< 1.1X upper normal institutional limits

• Calcium within normal institutional limits

• CPK, Troponin within normal institutional limits

• Uric Acid within normal institutional limits

• Ability to understand and the willingness to sign a written informed consent document; in addition to consent for the therapy, patients must give consent to required pre- and post-therapy blood and tissue samples;

Exclusion Criteria:

• Patients should not have had prior therapy with depsipeptide and may not be receiving any other investigational agents or drugs known to have histone deacetylase inhibitor activity such as sodium valproate

• Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events

• Significant cardiac disease including congestive heart failure that meets New York Heart Association (NYHA) class III and IV definitions (see Appendix II), history of myocardial infarction within one year of study entry, uncontrolled dysrhythmias, or poorly controlled angina

• History of serious ventricular arrhythmia (VT or VF, > 3 beats in a row), QTc > 500 msec, or LVEF < 40%

• Patients may not be co-medicated with an agent that causes QTc prolongation; - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements

• Not pregnant or lactating

• History of HIV infection

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Dana-Farber Cancer Institute	Boston	Massachusetts	United States	02115
2	Montefiore Medical Center	Bronx	New York	United States	10467-2490

Sponsors and Collaborators

• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Missak Haigentz, Montefiore Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: National Cancer Institute (NCI)
• ClinicalTrials.gov Identifier: NCT00084682
• Other Study ID Numbers: NCI-2013-00027; MMC 04-02-025S; N01CM62204
• First Posted: Jun 11, 2004
• Last Update Posted: Mar 5, 2021
• Last Verified: Feb 1, 2021

• Additional relevant MeSH terms: Carcinoma; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Romidepsin

Study Results

Participant Flow

Recruitment Details	A total of 14 patients were enrolled from one institution between June 2005 and October 2008

Arm/Group Title	Treatment (Romidepsin)
Arm/Group Description	Patients receive FR901228 (depsipeptide) IV at 13 mg/m2 over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV
Period Title: Overall Study
STARTED	14
COMPLETED	13
NOT COMPLETED	1

Baseline Characteristics

Arm/Group Title	Treatment (Romidepsin)
Arm/Group Description	Patients receive FR901228 (depsipeptide) IV at 13 mg/m2 over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV
Overall Participants	14
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	59.0
Sex: Female, Male (Count of Participants)
Female	3 21.4%
Male	11 78.6%
Race/Ethnicity, Customized (participants) [Number]
White	7 50%
Black	1 7.1%
Hispanic	6 42.9%

Outcome Measures

1. Primary Outcome

Title	Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease)
Description	Tumor response was assessed every eight weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions as assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable disease (SD) was defined as having no evidence of response (CR or PR) as best response to therapy, and no evidence of disease progression (appearance of new lesions or >/= 30% increase in target lesions) at 8 weeks.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Treatment (Romidepsin)
Arm/Group Description	Patients receive FR901228 (depsipeptide) IV at 13 mg/m^2 over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV
Measure Participants	13
Stable Disease	2 14.3%
Disease progression	9 64.3%
Symptomatic deterioration	2 14.3%

2. Secondary Outcome

Title	Duration of Response
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Data not collected. As the first stage goal of 8 patients with disease control was not achievable, further analysis was not done.

Arm/Group Title	Treatment (Romidepsin)
Arm/Group Description	Patients receive FR901228 (depsipeptide) IV at 13 mg/m2 over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV
Measure Participants	0

3. Secondary Outcome

Title	Time to Progression
Description	All time to event endpoints will be evaluated using Kaplan Meier estimates and survival curves will be generated based on these estimates.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

Data not collected. As the first stage goal of 8 patients with disease control was not achievable, further follow up was not done.

Arm/Group Title	Treatment (Romidepsin)
Arm/Group Description	Patients receive FR901228 (depsipeptide) IV at 13 mg/m2 over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV
Measure Participants	0

4. Secondary Outcome

Title	Overall Survival
Description	All time to event endpoints will be evaluated using Kaplan Meier estimates and survival curves will be generated based on these estimates. One and two-year survival and median survival time (if attained) will be estimated and reported with 95% confidence limits. If the sample sizes are sufficient, subgroup analysis based on baseline factors will be performed using the log rank test to compare survival curves.
Time Frame	Up to 2 years

Outcome Measure Data

Analysis Population Description

data not collected

Arm/Group Title	Treatment (Romidepsin)
Arm/Group Description	Patients receive FR901228 (depsipeptide) IV at 13 mg/m^2 over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV
Measure Participants	0

Adverse Events

Arm/Group Title	Treatment (Romidepsin)
Arm/Group Description	Patients receive FR901228 (depsipeptide) IV at 13 mg/m2 over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. romidepsin: Given IV
All Cause Mortality
	Treatment (Romidepsin)
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	Treatment (Romidepsin)
	Affected / at Risk (%)	# Events
Total	12/14 (85.7%)
Blood and lymphatic system disorders
Anemia	2/14 (14.3%)	14
Gastrointestinal disorders
Nausea	1/14 (7.1%)	1
Vomiting	2/14 (14.3%)	2
General disorders
Fatigue	5/14 (35.7%)	5
Infections and infestations
Lung infection	3/14 (21.4%)	3
Soft tissue infection	1/14 (7.1%)	1
Investigations
Thrombocytopenia	2/14 (14.3%)	2
Metabolism and nutrition disorders
Anorexia	2/14 (14.3%)	2
Vascular disorders
Hypotension	1/14 (7.1%)	1
Thrombosis	1/14 (7.1%)	1
Other (Not Including Serious) Adverse Events
	Treatment (Romidepsin)
	Affected / at Risk (%)	# Events
Total	11/14 (78.6%)
Gastrointestinal disorders
Constipation	6/14 (42.9%)	6
Diarrhea	2/14 (14.3%)	2
Dyspepsia	1/14 (7.1%)	1
General disorders
Pain	1/14 (7.1%)	1
Vascular disorders
Hypertension	1/14 (7.1%)	1

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.